Phoenix Rising supports the Millions Missing global day of protest
Phoenix Rising is delighted to support the demands being made in the ME/CFS community’s first-ever global day of protest …
Discuss the article on the Forums.

Combination of immunoglobulins and natural killer cells in the context of CMV and EBV infection

Discussion in 'Other Health News and Research' started by Ema, Apr 29, 2014.

  1. Ema

    Ema Senior Member

    Messages:
    4,276
    Likes:
    5,979
    Midwest USA
    Med Microbiol Immunol. 2014 Apr;203(2):115-23. doi: 10.1007/s00430-013-0321-2. Epub 2013 Dec 15.
    Combination of immunoglobulins and natural killer cells in the context of CMV and EBV infection.
    Frenzel K1, Lehmann J, Krüger DH, Martin-Parras L, Uharek L, Hofmann J.
    Author information

    Abstract
    Cytomegalovirus (CMV)-specific hyperimmunoglobulin (CMV-HIG) is used to treat and prevent CMV infection in immunocompromised patients, and anti-CD20 monoclonal antibody is successfully used in the treatment for post-transplant lymphoproliferative disease caused by Epstein-Barr virus (EBV).

    Two immunological approaches have been suggested to further improve the control of viral reproduction in patients with active disease: first, the use of monoclonal antibodies with specificity against viral epitopes and second, coadministration of cells with the capacity to promote antibody-dependent cell-mediated cytotoxicity.

    Here, we have evaluated the effectiveness of these strategies in vitro (alone and in combination) with neutralization and cytotoxicity assays. Our results indicate that monoclonal antibodies (in particular SM5-1) can be as effective as CMV-HIG in neutralizing-cell-free CMV.

    Moreover, our data indicate that antibody-mediated elimination (either by moAb or by HIG) of EBV-infected cells can be significantly enhanced by NK cells. Using human NK cells that have been purified, cultured and expanded under GMP conditions, we were able to demonstrate that the combination of NK cells and antibodies could represent a feasible and highly effective clinical approach to achieve control of EBV infections.

    Especially in leukopenic patients with low numbers of ADCC-promoting cells, the combination of adoptively transferred NK cells and antiviral antibodies offers a promising strategy that should be tested in clinical trials.

    PMID:

    24337366

    [PubMed - in process]
     
    Simon, Blue and heapsreal like this.
  2. Ema

    Ema Senior Member

    Messages:
    4,276
    Likes:
    5,979
    Midwest USA
    Yeah, like tomorrow, please!
     
    SOC and shannah like this.
  3. tdog333

    tdog333 Senior Member

    Messages:
    158
    Likes:
    108
    Have you tried Transfer Factor or Pro-Boost? They do similar, I think there are certain transfer factors that are more effective at certain strains.
     
  4. Ema

    Ema Senior Member

    Messages:
    4,276
    Likes:
    5,979
    Midwest USA
    Yes, I've tried them both...
     
  5. Martial

    Martial Senior Member

    Messages:
    1,342
    Likes:
    1,177
    Ventura, CA
    I wonder how this ties in with things like non hodgkins lymphoma.. From my understanding long term infections such as these can often trigger it due to the constant creation and demand of leukocyte cells, and lymph system complications?
     

See more popular forum discussions.

Share This Page